Imavita is proud to announce the recent acquisition of a new Bioluminescence imaging (BLI 2D/3D) / Fluorescence imaging (FLI 2D) imaging apparatus to help in development of preclinical models.

Since December 2022, Imavita is working on this innovative imaging system (Newton 7.0 / Vilber) which will permit to generate non-invasive, bioluminescence imaging (BLI) and fluorescence imaging (FLI) quantitative data for pre-clinical models in place at Imavita in Applications of interest, and principally in the area of drug disposition (PK and PK/PD), oncology, osteo-articular disease and dermatology.

Bioluminescence imaging / BLI is available in 2D, but also in 3D (BLI tomography). Fluorescence imaging (FLI) is available in 2D.

This new apparatus will permit in vivo and ex vivo imaging for:

  • Monitoring the development of tumors and infections
  • Tracking cell migration
  • Targeting Biodistribution of drugs, molecules and nanoparticles
  • Visualization of vasculature and microcirculation

The benefits of this in vivo imaging modality are:

  • Easily and efficiently obtain calibrated quantitative data in preclinical models
  • Deepen understanding of disease mechanisms, disease progression and therapeutic responses
  • Manage costs and capture time course data by avoiding sacrifice of animal models

For more informations, do not hesitate to contact us.

Categories: News

About the Author

Eric Lacoste ()

Veterinary with experience in biomarkers / imaging of preclinical species Founder of the company Imavita